MYO stock forecast, quote, news & analysis
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders... Show more
Myomo (MYO) Stock Analysis: Navigating Volatility in Wearable Robotics
- Myomo's stock has traded in a tight range near 52-week lows around $0.74, reflecting broader small-cap pressures amid stagnant recent news flow.
- Q3 2025 revenue hit $10.1 million, up 10% year-over-year, with record orders signaling pipeline strength despite guidance cuts earlier in the year.
- Analysts maintain a consensus "Strong Buy" rating with an average price target of $5.00, implying substantial upside potential.
- International and U.S. orthotics & prosthetics channels drove growth, though margins faced headwinds from higher costs.
- Year-to-date 2025 revenue guidance reiterated at $40-42 million, focusing on Medicare expansion and operational leverage.
- Upcoming Q4 earnings in March 2026 expected to provide clarity on path to profitability.
Current Market Snapshot
Myomo (MYO) stock has navigated choppy waters in recent trading sessions, hovering near its 52-week low amid low volume and absence of fresh catalysts. The shares reflect ongoing challenges in the small-cap medical device space, where investor sentiment remains cautious despite underlying operational progress. Revenue growth from Medicare Part B reimbursements and expanding orthotics channels has supported fundamentals, but margin compression and revised guidance have capped enthusiasm. Broader market cycles favoring large-cap stability have pressured MYO, yet analyst conviction points to undervaluation relative to long-term neurorehabilitation demand.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots, drawn from hundreds of algorithms that analyze and trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies—from high-frequency scalping on 5- or 15-minute charts to momentum plays on 60-minute timeframes—tailored to varying market volatility levels (low, medium, high). Standouts include agents delivering annualized returns up to 313%, win rates of 70-95%, and profit factors exceeding 12.5, often in sectors like semiconductors, biotech, and leveraged ETFs. For instance, multi-agent systems targeting volatility in small caps have posted 236% annualized gains with $42,000+ in modeled P/L over short periods. Only bots demonstrating superior risk-adjusted performance under current conditions earn a trending spot, helping traders adapt to shifting dynamics. Explore these tools to potentially enhance your MYO analysis with data-driven signals.
Recent Developments Driving MYO Price Action
In the past 30 days, Myomo (MYO) has seen no major company-specific announcements, contributing to range-bound trading near $0.74-$0.82 amid declining volumes averaging under 400,000 shares daily. The stock dipped approximately 15% from early January peaks around $0.96, aligning with small-cap rotation out of high-beta names as investors favored stability in a choppy market environment.
The absence of fresh news follows Q3 2025 results released November 10, which continue to shape sentiment. Revenue reached a robust $10.1 million, up 10% year-over-year and beating estimates by 5.5%, fueled by 186 MyoPro units delivered (16% increase) and a record 229 authorizations/orders—the strongest quarter yet. International revenues surged 63% to $1.8 million, while U.S. orthotics & prosthetics (O&P) channel rocketed 154%, reflecting successful network expansion. Year-to-date revenue hit $29.6 million, a 44% jump, with Medicare Part B comprising over 50% in prior quarters post-CMS brace reclassification in April 2024.
However, challenges emerged: gross margins slipped to 63.8% from 75.4% due to a 5% average selling price drop, elevated material/labor costs, and overhead. Net loss widened to $3.7 million ($0.09/share, better than expected -$0.11), with adjusted EBITDA at -$2.7 million. Management reiterated full-year 2025 guidance at $40-42 million (down from prior $50-53 million), citing lead quality shifts and pipeline conversion tweaks, which initially pressured shares post-Q2 but stabilized with Q3 beats.
Strategic moves bolstered liquidity: a $17.5 million debt facility with Avenue Capital (November 4, $12.5 million funded) lifted pro forma cash to $20.1 million. Private payer contracts now cover 27 million lives, and manufacturing ramps toward 250 units monthly. Analyst Ascendiant Capital (November 21) held "Buy" but trimmed target to $10 from $10.5, joining consensus at $5 average (Strong Buy from 5 firms).
Macro factors, including potential tariffs on imported components (motors, batteries), pose minor gross margin risks (~100 bps hit estimated), but no retaliatory issues noted for exports to Germany. Investor Rosalind Advisors upped stake to 9.99% (February 11 filing), signaling confidence. Overall, quiet recent weeks mask solid execution, with Q4 earnings (est. March 10) poised to highlight Medicare velocity and O&P scaling. (512 words)
2026 Outlook and Key Factors to Monitor
As Myomo advances through 2026, focus shifts to scaling Medicare Part B adoption, O&P network growth, and international traction amid neurorehabilitation demand from an aging population. Analysts project revenue around $47 million, up 17% from 2025 guidance, with EPS improving toward breakeven as gross margins target 200 bps expansion via manufacturing efficiencies and higher volumes.
Opportunities include MyoPro2+ enhancements, MyoPal pediatric launch, and China joint venture NMPA approval for 14 million potential patients. Private payer expansions (e.g., BCBS plans covering 18+ million lives) and 100+ German O&P clinics could diversify beyond Medicare (projected 22%+ mix). R&D investments in MyoPro3 platform promise computational and biosensing advances.
Risks encompass reimbursement hurdles from Medicare Advantage denials, tariff impacts on imports, and competition post-MIT patent expiry. Ongoing cash burn requires vigilant working capital management, with $20 million liquidity providing runway but dilution sensitivity if growth lags. Competitive positioning in wearable robotics hinges on clinician adoption and payer policies. Investors should track Q1 2026 earnings for pipeline velocity (1,669+ candidates), unit deliveries, and margin trajectory toward 70-72% long-term goals. (198 words)
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
MYO's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for MYO turned positive on May 20, 2026. Looking at past instances where MYO's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 19, 2026. You may want to consider a long position or call options on MYO as a result. In of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where MYO advanced for three days, in of 263 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 42 cases where MYO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MYO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MYO broke above its upper Bollinger Band on June 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.624) is normal, around the industry mean (10.958). P/E Ratio (0.000) is within average values for comparable stocks, (63.629). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.746). MYO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (1.337) is also within normal values, averaging (26.468).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MYO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MYO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of neuro-robotic technology
Industry MedicalNursingServices